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Small cell lung cancer (SCLC) is an aggressive neuro-
endocrine tumor, and no effective treatment is avail-
able to date. Mouse models of SCLC based on the
inactivation of Rb1 and Trp53 show frequent amplifi-
cations of the Nfib and Mycl genes. Here, we report
that, although overexpression of either transcription
factor accelerates tumor growth, NFIB specifically
promotes metastatic spread. High NFIB levels are
associated with expansive growth of a poorly differ-
entiated and almost exclusively E-cadherin (CDH1)-
negative invasive tumor cell population. Consistent
with the mouse data, we find that NFIB is overex-
pressed in almost all tested human metastatic high-
grade neuroendocrine lung tumors, warranting
further assessment of NFIB as a tumor progression
marker in a clinical setting.INTRODUCTION
Small cell lung cancer (SCLC) is the most aggressive subtype of
lung cancer and is characterized by early metastatic spread to
multiple organs (Byers and Rudin, 2015). It is most often diag-
nosed at an advanced stage of disease and is generally fatal
within 4 months if left untreated. Another striking feature of
SCLC is its exceptional initial response to standard first line
chemotherapy regimens, which is followed by rapid relapse of
chemoresistant tumors, limiting the survival benefit for SCLC pa-This is an open access article under the CC BY-Ntients (Byers and Rudin, 2015). The results of numerous clinical
trials testing distinct therapeutic approaches for SCLC have
been disappointing, and treatment programs have not changed
in the last three decades (Byers and Rudin, 2015). Due to its met-
astatic nature at presentation, SCLC is rarely resected, leading
to a scarcity of tumormaterial for analysis. In this context, mouse
models of SCLC provide a powerful tool to study the biology of
SCLC initiation, progression, and mechanisms of resistance
(Kwon and Berns, 2013).
We have previously generated a mouse model of SCLC based
on conditional inactivation of the tumor suppressor genes, Trp53
and Rb1, both of which are deleted in nearly all human SCLC
cases (George et al., 2015; Meuwissen et al., 2003). The model
recapitulates many salient features of SCLC, including its local-
ization, metastatic progression, and histopathological charac-
teristics (Gazdar et al., 2015; Meuwissen et al., 2003). In this
model, recurrent genetic alterations included losses on chromo-
somes 8, 12, 14, 16, and 19 and both gains and losses on chro-
mosome 4 (Dooley et al., 2011; McFadden et al., 2014). They
likely provide a selective advantage to tumor cells during tumor
evolution andmay harbor driver genes in case of gene amplifica-
tion. Chromosome 4 in particular often shows a number of
genomic alterations such as focal deletions encompassing
miR200a/miR200b, the hairy enhancer of split family of transcrip-
tion factors (Hes2, Hes3, and Hes5), Trp73, and two focal ampli-
fications, one encompassingMycl and anotherNfib (Calbo et al.,
2011; McFadden et al., 2014).
MYCL is a basic-helix-loop-helix transcription factor reported
to be an oncogene in SCLC. Several studies applying exome
and whole genome sequencing reported recurrent amplification
of the MYC family of oncogenes, including MYCL in SCLCCell Reports 16, 631–643, July 19, 2016 ª 2016 The Author(s). 631
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
(6.9%–9%) (Calbo et al., 2011; George et al., 2015; Iwakawa
et al., 2013). In line with this observation, targeted overexpres-
sion ofMycl in amousemodel vastly accelerated tumor develop-
ment (Huijbers et al., 2014).
NFIB belongs to the nuclear factor 1 (NFI) family of transcrip-
tion factors. They were found as factors essential for adenovirus
replication, but are now known to control expression of a large
number of cellular genes (Gronostajski, 2000; Harris et al.,
2015). The four members in vertebrates, NFIA, NFIB, NFIC,
and NFIX, can bind as hetero and homodimers to the
TTGGC(N5)GCCAA dyad symmetric consensus sequence and
either activate or repress transcription depending on the context
(Harris et al., 2015). They are expressed in multiple organ sys-
tems in partially overlapping patterns and play an important
role in regulating tissue-specific expression programs (Harris
et al., 2015). NFIB regulates proliferation and epithelial differen-
tiation during lung maturation, and NFIB knockout animals
have severe lung hypoplasia and developmental defects in the
brain (Hsu et al., 2011; Steele-Perkins et al., 2005). In addition,
it was reported to coordinate epithelial-melanocyte stem cell
proliferation and differentiation in hair follicles, where it was
shown to regulate the expression of 1,449 target genes (Chang
et al., 2013). In the brain, NFIB regulates the differentiation of
neural progenitor cells (Piper et al., 2014).
Several reports have defined NFIB as an oncogene (Dooley
et al., 2011; Zhang et al., 2015). The chromosomal region encod-
ing NFIB is amplified in patients with triple-negative breast
cancer (Han et al., 2008), in patients with squamous cell carci-
noma of the esophagus (Yang et al., 2001), and in submandibular
gland carcinoma (Andreasen et al., 2016). Increased NFIB
levels are also found in metastatic giant cell tumors of bone
and are associated with an elevated risk of metastasis (Mosa-
khani et al., 2013; Quattrini et al., 2015). Using SCLC cell lines
from both patients and mouse models, NFIB was shown to
regulate apoptosis, senescence, and proliferation and to allow
for anchorage-independent growth of fibroblasts (Dooley et al.,
2011).
In contrast to MYC family genes, NFIB is amplified in a very
limited number of human SCLC cases (George et al., 2015; Iwa-
kawa et al., 2013). Considering the high frequency of its focal
amplification in mouse, and its oncogenic potential in vitro, we
decided to test howNFIB expression affects SCLC development
in vivo and to examine its potential role in human SCLC.
RESULTS
NFIB Accelerates SCLC Initiation and Progression
To assess the role of NFIB in driving SCLC, we generated two
transgenic mouse strains that overexpressed Nfib concomitant
with Trp53 and Rb1 loss, one expressing full-length Nfib
(variant 1) and the other a shorter Nfib version lacking exons
9–11 (variant 3) (Figure S1A). Both variants contain the
conserved DNA binding domain; however, the shorter one lacks
a putative proline-rich transactivation domain at the C terminus
(Gronostajski, 2000; Mermod et al., 1989). Both are expressed
in normal mouse lung and in SCLC tumors of the Rb1F/F;
Trp53F/F mouse model (Figure S1B). The targeted transgenes
allowed for expression of the transgenic Nfib and firefly Lucif-632 Cell Reports 16, 631–643, July 19, 2016erase (Luc) upon CRE mediated inversion (Figure S1C). Mouse
models carrying similar targeted transgenes for either Mycl-
Luc or Luc have been described previously (Huijbers et al.,
2014). Four cohorts of animals were generated and analyzed
in parallel as follows: (1) a control cohort of Rb1F/F;Trp53F/F
and invCAG-Luc;Rb1F/F;Trp53F/F mice, (2) a Mycl cohort of
invCAG-Mycl-Luc;Rb1F/F;Trp53F/F mice, (3) an Nfib cohort
of invCAG-Nfib_v1-Luc;Rb1F/F;Trp53F/F and invCAG-Nfib_v3-
Luc;Rb1F/F;Trp53F/F mice, and (4) an Nfib/Mycl cohort generated
by crossbreeding of invCAG-Nfib_v1-Luc;Rb1F/F;Trp53F/F with
invCAG-Mycl-Luc;Rb1F/F;Trp53F/F animals. The Nfib cohort con-
tained both Nfib variants, since no significant differences were
observed between them with regard to the parameters analyzed
in this study. The Nfib/Mycl cohort was included to test whether
NFIB can augment SCLC progression in combination with the
strong oncogene MYCL and to gain insight into the selective
pressure conferred by the frequent co-occurrence of Nfib and
Mycl amplifications. All animals were injected intra-tracheally
with adenovirus carrying the CRE recombinase driven from the
ubiquitous CMV promoter. CRE expression resulted in the dele-
tion of Trp53 and Rb1 and transcriptional activation of the trans-
genes (Figure S1D).
To monitor the dynamics of tumor development, we used
bioluminescence imaging (Figures 1A and 1B). Control and
Nfib cohort animals exhibited a similar tumor growth pattern,
with a minimal increase in signal during the first weeks followed
by a sharp switch to exponential growth. This switch occurred
earlier in the Nfib cohort (median of 175 days) than in the control
cohort (median at 201 days) (Figures 1A and 1B). In contrast, an-
imals in both Mycl and Nfib/Mycl cohorts showed an exponential
increase in the signal soon after its first detection with a median
switch time of 109 and 89 days for Mycl and Nfib/Mycl, respec-
tively (Figures 1A and 1B). The pattern of luciferase signal directly
correlated with survival in the four cohorts (Figure 1C). Animals
in the control group had the longest latency with a median of
235 days. NFIB overexpressing animals had a significantly
decreased tumor latency (median survival of 193 days), with
the two transcript variants in the Nfib cohort showing indistin-
guishable tumor acceleration when analyzed separately (Fig-
ure S1E). Mycl animals had decreased tumor latency as
compared to both the control and Nfib mice (median latency of
146 days). A combination of NFIB and MYCL overexpression
decreased tumor latency further to a median of 132 days. There-
fore, NFIB and MYCL co-expression enhances SCLC develop-
ment, consistent with their frequent co-amplification in mouse
SCLC (Dooley et al., 2011).
To characterize the early stages of tumor formation, we sacri-
ficed animals at distinct time points post-virus injection, starting
at 70 days. Based on the luciferase signal, we did not expect any
lesions in control and Nfib animals at that stage and expected
some initial lesions in Mycl and Nfib/Mycl animals. Therefore,
we included only one Mycl and one Nfib/Mycl mouse at this
time point. Indeed, most of the lung was normal in both geno-
types, with only four small hyperplastic lesions in each (Figures
1D, S2A, and S2B). We next collected lungs from animals in all
groups 98 days following virus injection. No lesions were identi-
fied in the control cohort (three mice), and one lesion was found
in one out of three lungs of the Nfib cohort. In contrast, bothMycl
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Figure 1. NFIB Accelerates Tumor Initiation and Progression in a Mouse Model of SCLC
(A) Schematic representation of the switched targeted transgene and measurements of luciferase activity from thorax over time following viral induction.
(B) Time point (in days) at which linear growth switched to exponential growth based on luciferase signal.
(C) Survival curves of animals within the four cohorts.
(D) Quantification of lesions (initial and advanced) at 70, 98, and 140 days following viral induction.
(E) A representative H&E staining of advanced lung lesions (taken from the control cohort, 193 days post-induction).
(F) Synaptophysin (SYN) staining of the same lung as in (E).
Error bars in (B) and (D) represent mean ± SEM.
See also Figures S1, S2, and S3.and Nfib/Mycl cohorts had multiple initial lesions (average 16.7
and 12 in Mycl and Nfib/Mycl, respectively, 3 lungs each). In
addition, one Mycl lung and all three Nfib/Mycl lungs contained
one or two advanced lesions (Figures 1D, S2C, and S2D). At
140 days following tumor induction, our final collection time
point, animals in the control cohort showed minimal evidence
of tumor initiation (a single lesion in one out of four lungs) (Fig-ure 1D). In contrast, the Nfib cohort contained multiple initial
lesions (average of 8.3, four lungs), and one out of four lungs con-
tained two advanced lesions (Figure 1D). At the same time point,
both Mycl and Nfib/Mycl animals had multiple initial and
advanced lesions, with an average of 12 initial and 4.7 advanced
for Mycl, and 11 initial and 7 advanced for Nfib/Mycl (Figures 1D,
S2E, and S2F). Initial lesions in the control cohort becameCell Reports 16, 631–643, July 19, 2016 633
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Figure 2. NFIB Is Associated with Increased
Chromosomal Instability
(A and B) Copy number of Nfib (A) and Mycl (B)
genomic locus in control, Mycl, and Nfib cohort tu-
mors. The dotted line indicates the threshold.
(C and D) Genomic rearrangement and copy-num-
ber alterations on chromosome 4 in control (C) and
Nfib (D) tumors. Line coloring indicates orientation
of fusion ends.
(E and F) Total number of copy-number aberration
(CNA) events on chromosome 4 (E) and in the whole
genome (F) in different tumor classes (indicated
by *). Copy-number gain (log2 ratio > 0.459) and loss
(log2 ratio < 0.67).
Data are mean ± SEM.evident at 175 days post-injection (data not shown). Thus, over-
expression of Nfib accelerated tumor initiation by 5 weeks, while
overexpression of Mycl and Nfib/Mycl accelerated tumor initia-
tion by 15 weeks.
We next performed a detailed histological evaluation of ani-
mals sacrificed due to respiratory distress. Full necropsy was
carried out, and tissues were sectioned and stained with H&E.
A range of lesions from atypical hyperplasia and intraepithelial
neoplasia to advanced SCLC were identified in lung sections
from animals in all groups. They were mainly located in the cen-
tral lung and frequently within the mediastinum (Figure 1E).
Peripheral lesions within the alveolar compartment were also634 Cell Reports 16, 631–643, July 19, 2016found. Next, we stained lung sections
with markers of neuroendocrine (NE) dif-
ferentiation (synaptophysin, chromogra-
nin, NCAM, and CGRP). All lesions were
positive for these markers, confirming their
NE origin (Figure 1F; data not shown).
Interestingly, 10 out of 29 of the Nfib/Mycl
animals and 4 out of 26 of the Nfib animals
developed NE tumors within the trachea
(Figures S3A–S3C). This was evident from
both the luciferase imaging and histologi-
cal evaluation (Figures S3A and S3B).
This phenotype was driven by NFIB,
as none of the Mycl mice (0 out of 32)
had tumors in the trachea (Figure S3C).
Interestingly, while NE cells within the cen-
tral lung are mostly found in clusters
(neuroendocrine bodies), NE cells in the
trachea appear as single cells (Figures
S3D and S3E).
Thus NFIB significantly accelerated tu-
mor initiation and progression in the lung
and supported tumor induction at a novel
location, the trachea.
NFIB Is Associated with
Chromosomal Instability
Focal amplifications of Nfib are frequently
observed in mouse SCLC model (Dooley
et al., 2011). However, other genes locatednear the Nfib locus are often co-amplified, e.g., Tyrp1, Mpdz,
Cer1, Frem1, Zdhhc21, and Psip1, some of which have previ-
ously been implicated in tumor development (Cerma´kova´ et al.,
2014; French et al., 2016; Ghanem and Fabrice, 2011). To
examine whether transgenicNfib expression is sufficient to elim-
inate the selective pressure for amplification of the correspond-
ing endogenous locus, the copy number of Nfib in tumors from
Nfibmice was examined using qPCR (Figures 2A and 2B). Previ-
ously we showed that the Mycl locus is not amplified in 95% of
tumors of Mycl mice, arguing that theMycl transgene abrogates
the requirement for its amplification (Figure 2B) (Huijbers et al.,
2014). Similarly, all tumors driven by theNfib transgene exhibited
Table 1. Classes Based on Status of Nfib and Mycl in the Tumor
Class
Mouse
Genotype
(Rb1F/F;P53F/F;
invCAG-)
Tumor
Genotype
(Endogenous
Locus)
Tumor Expression
(qPCR Relative
to Normal Lung)
Controla Luc (or WT) Nfib and Mycl
normal
and/or Nfib and Mycl
normal
Nfiba Nfib-Luc
Luc (or WT) Nfib,
copies > 8
and/or Nfib, REU > 8
Mycla Mycl-Luc
Luc (or WT) Mycl,
copies > 8
and/or Mycl, REU > 100
Nfib/
Mycla
Nfib-Luc;
Mycl-Luc
Nfib-Luc Mycl,
copies > 8
and/or Mycl, REU > 100
Mycl-Luc Nfib,
copies > 8
and/or Nfib, REU > 8
Luc (or WT) Mycl,
copies > 8
and Nfib,
copies > 8
and/or Mycl, REU > 100
and Nfib, REU > 8
aIndicates tumor class in figures. WT, wild type; REU, relative expression
units.a normal DNA copy number of the endogenous Nfib locus (Fig-
ures 2A and 2B). In combination with the accelerated SCLC tu-
mor growth, this formally proves that Nfib is a bona fide driver
of SCLC.
Amplification of theMycl locus was detected in 33% of tumors
in Nfib mice (6 out of 18 tumors). Conversely, the Nfib locus was
amplified in 3 out of 20 tumors (15%) in Mycl mice (Figures 2A
and 2B). These amplifications are in line with the reduced tumor
latency observed in the Nfib/Mycl cohort and support a selective
benefit for co-expression ofNfib andMycl in SCLC. In control tu-
mors, concurrent amplification of Nfib and Mycl is observed in
35% (9 out of 26) of cases (Figures 2A and 2B). These co-ampli-
fications are striking, since both genes are never part of the same
amplicon despite being juxtaposed on chromosome 4 (40.6 Mb
apart). To gain better insight into themechanism of co-amplifica-
tion, we performed mate-pair sequencing on tumors of control
and Nfib mice (Figures 2C and 2D). The tumors showed focal
amplifications on chromosome 4, including Nfib and/or Mycl
loci. We observed intrastrand chromosomal rearrangements
leading to a re-shuffle of the chromosome in three out of five
tumors examined. This type of intrastrand rearrangements
was only observed on chromosome 4. This suggests that these
rearrangements frequently occur simultaneously and are likely
the result of a single catastrophic event, in line with several
case reports for human SCLC (George et al., 2015; Iwakawa
et al., 2013; Stephens et al., 2011). Observed amplifications likely
reflect clonal evolution causing the heterogeneity we describe
below.
To obtain an estimate of the overall genomic stability in SCLC
in our mouse models, low-coverage whole genome sequencing
was performed on a panel of tumors. The tumors were dividedinto different classes based on the type of transgene, on the focal
amplification of either theNfib orMycl locus, and on their expres-
sion (Table 1). This division into classes allowed us to link
genomic aberrations to gene expression of Nfib alone (Nfib
class), Mycl alone (Mycl class), or both (Nfib/Mycl class). Both
control and Mycl class tumors had a limited number of copy-
number aberrations (CNAs). Surprisingly, Nfib class tumors
showed a significantly increased number of CNA events
compared to control and Mycl class tumors, and these chromo-
somal rearrangements were widely spread over the genome and
chromosome 4 (Figures 2E and 2F). Interestingly, we also
observed an increase in the number of CNA events when
comparing Nfib/Mycl to Mycl class, suggesting that chromo-
somal instability is specifically associated with Nfib overexpres-
sion (Figures 2E and 2F).
NFIB Changes the Metastatic Profile
One of the key characteristics of SCLC is its aggressive metasta-
tic dissemination. We therefore asked whether Nfib overexpres-
sion affected metastatic behavior of SCLC cells. The original
Trp53;Rb1 SCLC mouse model primarily shows metastasis to
the liver (Meuwissen et al., 2003). We stained livers with NCAM
antibody to identify NE metastatic lesions and quantified the
number of animals that carried liver metastasis within each of
the four classes (Table 1). Considering the prevalence of upper
airway lesions and associated early lethality, which likely pre-
vented full metastatic dissemination, animals carrying both
Nfib and Mycl transgenes were excluded from the analysis.
Only 1 out of 7 animals and 3 out of 13 animals in the control
and Mycl class, respectively, showed liver metastasis (Fig-
ure 3A). In contrast, the majority of animals in the two Nfib con-
taining classes had liver metastases. Specifically, 8 out of 10 Nfib
class animals and 17 out of 21 Nfib/Mycl class animals had mul-
tiple metastases in the liver (Figure 3A). Further characterization
of liver samples revealed that some livers contained only a few
foci, while others showed massive colonization by NCAM-posi-
tive cells. Also, metastatic foci themselves varied in size. There-
fore, we quantified both the number of foci and the relative area
of the liver occupied by metastases (Figures 3B and 3C). Control
class animals had on average 1.5 ± 1.5 and Mycl class animals
had 1 ± 0.6 metastatic foci per liver section. In contrast, Nfib
class animals contained on average 9.7 ± 3 foci and Nfib/Mycl
class animals 31 ± 10 foci per liver section (Figure 3B). The two
Nfib isoforms showed a similar pattern (Figure S4A). Also, the
area covered by liver metastases was significantly higher within
the two Nfib containing classes when compared to both control
and Mycl classes (Figure 3C). Importantly, all the liver samples
with the highest metastatic load belonged to Nfib/Mycl class,
while animals in the Nfib and Mycl classes had on average an in-
termediate and low tumor load, respectively (Figures 3B–3F).
NFIB also changed the metastatic profile. We noted metasta-
ses to kidney and bone (Figures 3G, S4B, and S4C). All these
cases belonged to either the Nfib or Nfib/Mycl class (Figures
3B, 3C, and 3H). In all instances, metastases were exclusively
composed of NE cells as judged by SYN and NCAM staining
and their morphology (Figures 3D–3F; data not shown). Thus,
NFIB promotes more extensive metastasis in the SCLC mouse
model.Cell Reports 16, 631–643, July 19, 2016 635
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Figure 3. NFIB Promotes Metastases and Changes the Metastatic Profile
(A) Percent of animals with and without liver metastasis in each of the four classes.
(B) Quantification of the number of liver metastasis in each class.
(C) Quantification of the percent area of the liver covered by metastatic lesions in each of the four classes. Circles with a shaded upper or lower half indicate
animals with kidney and bone metastasis, respectively. Circles marked with a central dot indicate animals with metastasis to both kidney and bone.
(D–F) Representative liver section from the three classes, Mycl (D), Nfib (E), and Nfib/Mycl (F), stained with NCAM to identify NE metastatic lesions.
(G) NE metastasis in the kidney, H&E.
(H) Percent of animals in each class with metastatic lesions outside the liver (bone, kidney).
(I) Number of animals in Mycl and Nfib/Mycl cohort that provided successful culture of NE cells from the blood.
Scale bars in (D)–(F), 200 mm. Scale bar in (G) represents 100 mm. See also Figure S4.The transgenic Nfib/Mycl cohort showed a relatively low inci-
dence of metastasis (7 out of 28 animals) (data not shown). To
test whether, despite early lethality and presence of upper airway
lesions, NFIB also conferred metastatic potential in the trans-
genic Nfib/Mycl cohort, we looked for the presence of circulating
tumor cells as a surrogate indicator of metastasis. In the absence
of a suitable surface marker that would allow us to reliably quan-
tify these cells, we collected blood fromanimals inMycl andNfib/
Mycl cohorts and initiated cultures using media that supports
growth of NE cells. The success rate of culturing NE cells was
significantly higher in Nfib/Mycl cohort animals (6 out of 10), as
compared to Mycl cohort animals (2 out of 11) (Figure 3I). One
of the two Mycl animals that did exhibit growth from circulating
tumor cells showed Nfib overexpression (20-fold increase by
qPCR), indicating that it actually should be counted as belonging
to the Nfib/Mycl class in this assay (data not shown). Therefore,
NFIB is supporting metastasis of the tumor cells by promoting636 Cell Reports 16, 631–643, July 19, 2016their intravasation, their survival, or both at early stages of
dissemination.
NFIB Activates a Migration and Survival Program
In order to identify the putative targets of NFIB and to understand
its role in tumor development and metastasis, we established
SCLC cell lines from Mycl cohort tumors with low NFIB expres-
sion. We overexpressed mouse Nfib in four of these cell lines to
examine the differential gene expression profiles (Figures S5A–
S5C). We observed 148 upregulated and 70 downregulated
genes following NFIB overexpression (Figure 4A; Table S1). To
identify the signaling networks likely responsible for driving tu-
mor progression, we performed functional clustering analysis
of the differentially expressed genes using the Ingenuity Pathway
Analysis. Analysis of upregulated genes showed significant
enrichment for cellular growth and proliferation, cellular move-
ment, and cell death and survival pathways (Figure 4B). 46 out
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Figure 4. Key Changes in Cancer Progres-
sion Following NFIB Overexpression In Vitro
(A) Analysis of the gene expression changes
following Nfib overexpression in four mouse SCLC
primary cell lines (heatmap). DEGswere selected if
expressed in at least three out of four samples.
Values are represented as log2 fold change. Red,
upregulated (average log2 fold change > 0.5);
green, downregulated genes (average log2 fold
change < 0.5).
(B) Ingenuity pathway analysis (IPA) of differentially
expressed genes based on Z score and p value.
The biological functions that are expected to be
increased according to the gene expression
changes in our dataset were identified using the
IPA regulation Z score algorithm (green dot). The
p value was calculated with the Fischer’s exact
test (p value% 0.05).
(C) Genes involved in cell movement. Orange
dashed line, predicting activation of cell move-
ment; green dashed line, unknown directionality;
black dashed line, effect not predicted.
(D) Validation of several genes in (C) by qPCR.
Error bars represent mean ± SD.
See also Figure S5 and Table S1.of 148 upregulated genes were implicated in cell motility, and 50
out of 148 upregulated genes were associated with cell death
and survival (Figure 4B). The cell motility category showed the
highest activation Z score of 3.83, strongly indicating that genes
upregulated following NFIB overexpression increased cell
motility (Figure 4C). Some of the upregulated genes that were as-
signed to cell movement, cell death, and survival were validated
by qPCR (Figure 4D; Figure S5D).
NFIB Drives Tumor Dedifferentiation and Invasion
The ability to metastasize is often associated with dedifferentia-
tion (Ellenbroek et al., 2012). Given the strong metastatic
behavior of NFIB expressing tumors, we asked whether NFIB
was associated with dedifferentiation. Indeed, early lesions
that were low or negative for NFIB expressed high levels ofCSYN, whereas lesions with strong NFIB
expression showed a clear reduction in
SYN (Figures 5A and 5B). Similarly, in
advanced lesions, the NFIB high (NFIBhi)
populations showed signs of dedifferenti-
ation, as judged by a decreased level of
SYN (Figures 5D, 5E, S6A, and S6B).
Another well-known prometastatic
feature is increased invasiveness and
decreased expression of adhesion mole-
cules, such as E-cadherin (CDH1). All
early lesions expressed CDH1, regard-
less of the NFIB level (Figures 5C and
S6C), whereas NFIBhi ‘‘dedifferentiated’’
populations within advanced lesions had
frequently lost this marker (Figure 5F).
Basedon the above,wepredicted an in-
crease in both dedifferentiation and inva-siveness within the Nfib cohort as compared to control and Mycl
cohorts. Indeed, a large proportion of the tumors in the lungs of
control and Mycl mice expressed high levels of CGRP and
CDH1 and showed limited invasion (Figures 5G and 5K; data not
shown). Still, we often found areas negative for CDH1 (CDH1)
juxtaposed toCDH1hi areas (Figures 5G, 5H, andS6D), the former
possibly resulting from reseeding events. The CDH1 cells ex-
pressed high levels of NFIB and were CGRP/SYNlo (Figures 5I,
S6E, and S6F). These NFIBhi/CGRPlo/CDH1 sub-populations
often presented as pools of dedifferentiated tumor cells that
invaded perivascular and peribronchial spaces, forming sheath-
like patterns that are indicative of their strong disseminating capa-
bility (Figures 5H, 5I, and 5L). Consistent with this, tumors in the
Nfib cohort were predominantly invasive and consisted primarily
of NFIBhi/CGRPlo/CDH1 cells (Figure 5J). Interestingly, whileell Reports 16, 631–643, July 19, 2016 637
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we often found scattered p44/42 MAPK-positive cells within
NFIBlo/CGRPhi/CDH1hi regions, theNFIBhi/CGRPlo/CDH1 areas
were invariably p44/42-negative (Figures S6G–S6I).
All tumors, irrespective of NFIB levels, expressed ASCL1, a
factor required for SCLC survival, and SOX2, shown to be ampli-
fied in a subset of SCLCs (Augustyn et al., 2014; Rudin et al.,
2012). TTF1, also often expressed in SCLC (Travis, 2012),
showed variable levels without a clear correlation with NFIB
staining (data not shown).
Lungs fromanimals inall cohortscontained frequent vascular in-
vasions that were already present early on following tumor induc-
tion (Figure S7A). To define invasion routes, we stained sequential
lung sections with SYN, CD31, and podoplanin to mark NE cells,
blood, and lymph vessels. NE cells were found in clusters and
invaded mainly lymph vessels (Figures S7B and S7C; data not
shown). Both CDH1+ and CDH1 cells could be found within ves-
sels (Figure S7D). NFIB levels were moderate to high in NE cells
present in lymph vessels (Figures S7E and S7F) and correlated
with a stronger lymphovascular invasion (LVI) phenotype.
Given theabundantLVIs inourmousemodelwewerecurious to
see whether the LVIs previously reported for human SCLC show
prominent expression of NFIB. Histological sections of SCLC
frompatients inwhich this could beassessedare not readily avail-
able. However, we did obtain sections from a human large cell
neuroendocrine carcinoma (LCNEC) that showed LVIs (Fig-
ure S7G). Consistent with the mouse data, NE cells in these sec-
tionswereNFIBhi (Figure S7H)while beingCDH (FigureS7I). This
suggests that the process of tumor progression in high-grade NE
tumorsmay also be linked to NFIB expression in humans. Indeed,
critical driver lesions (RB1, p53, MYC, and NFIB) and changes in
the expression of differentiation markers (CDH1, CGRP, SYN) as
well as the route of tumor dissemination (LVI) are shared features
of SCLC in humans and mice (Figures 5K and 5L).
NFIB Expression Is Correlated with Metastatic Disease
in Human SCLC and LCNEC
The phenotypes described above point to the importance of
NFIB in the acquisition of a high-grade invasive, dedifferentiated,
andmetastatic tumor state. We therefore tested whether NFIB is
expressed in pulmonary neuroendocrine tumors (pNETs) of
various grades. According to the recent edition of the World
Health Organization, pNETs are classified into low-grade typical
carcinoids (TCs), intermediate grade atypical carcinoid (AC), and
high-grade NE carcinomas, the latter including both (LCNEC and
SCLC) (Travis et al., 2015). We retrieved a panel of 48 pNET tu-
mor samples from the archive of the Antoni van Leeuwenhoek
hospital. The panel included TC, AC, LCNEC, and SCLC cases.Figure 5. NFIB Drives Tumor Dedifferentiation and Invasion
(A–C) Early lesions NFIB (A), SYN (B), and CDH1 (C) staining, respectively (Nfib c
(D–F) Advanced lesion NFIB (D), SYN (E), and CDH1 (F) staining, respectively (M
(G) Whole lung, CDH1 staining (Mycl cohort).
(H and I) Part of the lung indicated with dotted area in (G), CDH1 (H) and NFIB (I
(J) Whole lung, CDH1 staining (Nfib cohort).
(K and L) Diagrams of tumor growth and local and distant metastatic dissemin
overexpression, intrapulmonary dissemination and metastatic load in liver is v
dissemination, large metastatic load in the liver, and metastasis to kidney and b
Scale bars in (A)–(F) represent 100 mm. Scale bars in (H) and (I) represent 500 mmStrikingly, while being absent or weakly expressed in all TC (10)
(Figures 6A, 6B, and 6M) and in all AC (6) samples (Figures 6D,
6E, and 6M), NFIB was highly expressed in 22 out of 26 SCLC
samples, including those derived from primary (13 out of 15)
and metastatic (9 out of 11) sites (Figures 6J, 6K, and 6M). A sig-
nificant spread in NFIB expression was evident in LCNEC cases
(high expression in three out of six cases) (Figures 6G, 6H, and
6M). CDH1 expression showed an opposite trend, with rather
high expression in more differentiated, low- and intermediate-
grade TC and AC, and significantly lower average expression
in SCLC and LCNEC (Figures 6C, 6F, 6I, 6L, and 6N). Strikingly,
NFIBlo expressing cases showed significantly better overall sur-
vival compared to NFIBhi cases (Figure 6O). Further analysis of
patient data indicated that five out of seven NFIBlo cases repre-
sented low-stage SCLC and LCNEC (stage I/II), and none of the
NFIBlo category presented with stage IV disease characterized
by distant metastases. In contrast, 23 out of 24 patients in the
NFIBhi group for which we had records had stage III/IV disease.
These data fully align with the results obtained in our mouse
models.
DISCUSSION
Well-designed mouse models are invaluable for understanding
the processes underlying initiation, progression, and metastatic
spread of SCLC and to rationally design better intervention stra-
tegies (Semenova et al., 2015). This is particularly important in
view of the poor access to both early and progressed tumor le-
sions in patients. Several groups have successfully utilized
Rb1F/F;Trp53F/F mouse models to identify and validate other
oncogenic drivers, including MYCL, PTEN, and RBL2 as well
as NOTCH and Hedgehog pathway components (Gazdar et al.,
2015). Genome sequencing of human SCLC has pointed to a
number of additional drivers that likely lead to the variations we
observe in NE tumors. Here we show that NFIB is a prominent
driver in SCLC, with a key role in shaping the aggressive nature
of this tumor type.
NFIB Accelerates SCLC Initiation
We show that NFIB significantly accelerates SCLC initiation and
progression in our mouse models. Forced NFIB overexpression
allowed for more efficient and frequent initiation of NE lesions
and led to tumor development at new sites, i.e., trachea. The
striking predominance of tracheal lesions in the Nfib/Mycl cohort
(with several cases in the Nfib cohort) and its absence in theMycl
cohort supports the critical role of NFIB in the development of
these tumors. We hypothesize that the combination of theohort).
ycl cohort).
), respectively. Invasive sheaths indicated with arrowheads.
ation. NE tumor cells are abundantly found in lymph vessels. Without NFIB
ery limited (K). With NFIB overexpression, there is massive intrapulmonary
one (L).
. See also Figure S6.
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Figure 6. NFIB Marks Metastatic Disease in Patients
(A–C) Representative image of H&E (A), NFIB (B), and CDH1 (C) expression in typical carcinoid (TC).
(D–F) Representative image of H&E (D), NFIB (E), and CDH1 (F) expression in atypical carcinoid (AC).
(G–I) Representative image of H&E (G), NFIB (H), and CDH1 (I) expression in large cell NE carcinoma (LCNEC).
(J–L) Representative image of H&E (J), NFIB (K), and CDH1 (L) expression in SCLC.
(M and N) Quantification of NFIB (M) and CDH1(N) expression in human pNET samples, respectively.
(O) Survival curves of patients within high-grade pNET (LCNEC and SCLC).
See also Figure S7 and Table S2.single-cell nature of NE cells in the trachea and environmental
factors make these cells more refractory to tumor initiation and
that NFIB is required to overcome these less favorable condi-
tions for outgrowth.640 Cell Reports 16, 631–643, July 19, 2016NFIB Overexpression Is Associated with Increased
Chromosomal Instability
An unexpected observation was the increased chromosomal
instability in NFIB-driven tumors. Gene expression analysis did
not reveal a candidate gene or signature associated with the
control of cell replication or DNA repair. However, the increase
in chromosomal aberrations observed in NFIB overexpressing
cells may well be explained by a higher tolerance for chromo-
somal instability resulting from NFIB’s anti-apoptotic activity as
previously found in SCLC cell lines and mouse embryonic fibro-
blasts (Dooley et al., 2011).
NFIB Is a Potent Driver of Metastasis
We show that NFIB promotes metastasis not only by increasing
the local dissemination of the tumor cells within the lung but also
by altering their metastatic profile, permitting colonization of a
wider set of tissues. We identified gene signatures for prolifera-
tion and cellular movement imposed by NFIB overexpression
in mouse SCLC cell lines. The profiles were in line with the
observed phenotypes in the NFIB driven tumors and highlighted
the ability of NFIB to modify a number of distinct behavioral fea-
tures of NE cells, making themmore capable to invade and colo-
nize foreign sites.
We have previously shown that communication between NE
(p44/42-negative) and NonNE (p44/42-positive) cells is required
for efficient metastasis of subcutaneously grafted SCLC cells
(Calbo et al., 2011; Kwon et al., 2015). Interestingly, p44/22-pos-
itive cells were only found in NFIBlo regions. Although NonNE cell
cultures can be easily established from isolated tumors, their
identity in vivo remains elusive. It might be that these p44/42-
positive cells represent this NonNE population and that they
play their own specific role in assisting NE cell survival,
outgrowth, and dissemination.
NFIB Overexpression Results in Dedifferentiated
Aggressive Tumors
Tumors in our SCLC mouse models showed both differentiated
and dedifferentiated characteristics. High NFIB expression was
associated with dedifferentiation and invasive behavior evi-
denced by the presence of perivascular and peribronchial
sheath-like dissemination. This type of invasive behavior was
most prevalent in the Nfib cohort. In line with this, we found a
consistent negative correlation between the expression of
NFIB and NE differentiation markers in advanced lesions. Unlike
advanced lesions, a subset of NFIBhi early lesions showed high
levels of NE differentiation markers, indicating that NFIB-driven
dedifferentiation is at least in part a gradual process.
Once tumors start to progress, we see striking heterogeneity
with respect to CDH1 expression, loss of which has been asso-
ciated with metastatic spread (Schneider and Kolligs, 2015;
Singhai et al., 2011). All early lesions are CDH1+, in LVIs the
expression is heterogeneous, and it is lost in disseminated tu-
mors. Consequently, the CDH1 lesions might well have arisen
from reseeding events. The pattern of colonization within the
lung supports this. In conclusion, NFIB is critical for forcing dedif-
ferentiation of NE tumor lesions, thereby augmenting their inva-
sive behavior.
NFIB Regulation
NFIB belongs to a family of transcription factors capable of
binding and regulating a plethora of targets. This makes the
dissection of the exact molecular mechanisms underlyingNFIB-mediated oncogenic transformation a challenge. At the
same time, this multifaceted function might be needed for pro-
gression and colonization of new metastatic sites.
In contrast to the highly conserved N-terminal DNA binding
domain, the C-terminal region of NFIB diverges extensively be-
tween members of the NFI transcription factor family as well as
between isoforms (Liu et al., 1997). The C-terminal region en-
codes a putative transactivation domain (Mermod et al., 1989).
Overexpression of the two isoforms that differ in this C-terminal
region resulted in indistinguishable phenotypes. Therefore, the
role of this domain for tumor progression and metastasis ap-
pears to be negligible.
Little is known about the regulation of NFIB expression. The
transcription factor PAX6, a member of the paired box gene fam-
ily, has been shown to bind and regulate NFI family proteins,
including NFIB (Holm et al., 2007; Ninkovic et al., 2013). In addi-
tion, several microRNAs (mRNAs), such as miR-124, miR-1246,
and miR-153, have been reported to regulate NFIB (Tsai et al.,
2014; Wang et al., 2015; Zhang et al., 2015). These miRNAs
bind NFIB transcripts in the 30 UTR. Altered expression of these
miRNAs could therefore lead to NFIB upregulation in tumors.
It is worth noting that the mouse model brought NFIB to light,
which otherwise would have been overlooked due to paucity of
genomic aberrations encompassing the NFIB locus in human
SCLC. This also emphasizes the added value of monitoring
RNA and protein expression in parallel with the identification of
genomic aberrations. The importance of conducting such ana-
lyses at the single cell level is nicely illustrated by the extensive
and profound heterogeneity that we observe in mouse SCLC
and that is also seen in human SCLC.
NFIB Marks Metastatic Disease in Human SCLC and
LCNEC
The important role of NFIB in mouse SCLC prompted us to scru-
tinize its relevance for SCLC development in human. Utilizing a
panel of human pNETs, we could show that NFIB is often highly
expressed in NE human tumors, such as SCLC and LCNEC, as
compared to the low- and intermediate-grade cancers, such
as TC and AC.
Importantly, themajority of high-stage SCLC and LCNECwere
NFIBhi, whereas the few tumor samples that were NFIBlo repre-
sented mainly stage I/II cases, and consequently these patients
showed prolonged survival. This points to the biological signifi-
cance of NFIB in commanding a highly proliferative, dedifferenti-
ated, migratory, and invasive state that is a characteristic of met-
astatic disease in patients. Thedata are highly consistentwith our
results obtained in the mouse. When patients present with stage
I/II disease, high expression of NFIBmay already be indicative for
a high probability of early progression with micro-metastasis.
Therefore, our data point to a possible prognostic value of NFIB
and call for analysis of a large patient cohort. However, before
such prognostic marker can be useful, efficient early detection
methods (i.e., liquid biopsy sequencing) have to be in place.
In summary, high NFIB expression marks high-grade tumor
populations both in a mouse model of SCLC and in human
pNETs. The specific set of features influenced by NFIB makes
this transcription factor particularly potent in promoting tumor
progression and metastatic dissemination. Therefore, analysisCell Reports 16, 631–643, July 19, 2016 641
of targets downstream of NFIB and detailed dissection of molec-
ular mechanisms involved in NFIB driven phenotypes may help
to understand the key biological peculiarities of SCLC. In the
same vein it will be important to identify the gene(s) that control
the levels of NFIB as they likely serve as important master regu-
lators of metastasis.
EXPERIMENTAL PROCEDURES
More detailed procedures are described in the Supplemental Information.
Ethics Statement
The study was performed in accordance with the Dutch and European regula-
tions on care and protection of laboratory animals. All animal experiments
were approved by the local animal experimental committee, DEC NKI (OZP
ID: 10023).
Genetic Engineering in Rb1F/F;Trp53F/F ESCs and Generation
of Mice
The pFrt-invCAG-Nfib_v1-Luc and pFrt-invCAG-Nfib_v3-Luc vectors were
introduced in a rederived Col1a1-frt targeted Rb1F/F;Trp53F/F embryonic
stem cell (ESC) clone (NKI GEMM-ESC resource at www.infrafrontier.eu, clone
TMA11101) by means of Flpe-mediated transgene integration as described
(Huijbers et al., 2015).
DNA Sequencing and Copy-Number Profiling
Genomic DNA library was prepared by TruSeq DNA LT Sample Preparation kit
(Illumina) and was sequenced using an Illumina HiSeq2000/2500 machine ac-
cording to manufacturer’s instructions. To obtain copy-number profiles, we
used CopywriteR tool (Kuilman et al., 2015).
Next-generation MPS mate-pair libraries were prepared using the Nextera
Mate Pair Sample Preparation Kit (Illumina) (Stephens et al., 2011).
Human SCLC Patient Specimens
This study was approved by the institutional review board of the NKI-AVL. We
collected archived formalin fixed and paraffin embedded samples of 48 TC,
AC, LCNEC, and SCLC patients. The samples were primary and metastatic
tumors diagnosed as stage I/IV. The H-score was determined by assessing
the extent of immunoreactivity for NFIB and CDH1 (ECAD) by K.M. and
E.A.S. (Table S2). An H-score above 150 was considered NFIBhi. Overall sur-
vival was determined by the length of time from diagnosis to last date of follow-
up at which patients were still alive.
Statistical Analysis
Kaplan-Meier survival curves were analyzed using the log-rank test. All
p values were calculated using a nonparametric Mann-Whitney test. Data
shown in column graphs represent the mean ± SD. Statistical analyses were
performed by GraphPad Prism6.
ACCESSION NUMBERS
The accession number for the sequences reported in this paper is NCBI
BioProject: SRP075877. The accession number for RNA sequencing data is
GEO: GSE82005.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and two tables and can be found with this article online at
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